SCHEMBL2347914

SCHEMBL2347914

CC(C)(C)NC(=O)Nc1nc2nc(Nc3ccc4nonc4c3)ncc2cc1-c1c(Cl)cccc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 20/20 0.64
▸ FGFR2 P21802 6/20 0.64
▸ FGFR4 P22455 6/20 0.64
▸ FGFR3 P22607 6/20 0.64
▸ SRC P12931 11/20 0.63
▸ PDGFRB P09619 7/20 0.63
▸ PDGFRA P16234 7/20 0.63
▸ EGFR P00533 5/20 0.63
▸ PRKD3 O94806 3/20 0.63
▸ PRKCG P05129 3/20 0.63
▸ PRKCB P05771 3/20 0.63
▸ PRKCA P17252 3/20 0.63
▸ PRKCH P24723 3/20 0.63
▸ PRKCI P41743 3/20 0.63
▸ PRKCE Q02156 3/20 0.63
▸ PRKCQ Q04759 3/20 0.63
▸ PRKCZ Q05513 3/20 0.63
▸ PRKCD Q05655 3/20 0.63
▸ PRKD1 Q15139 3/20 0.63
▸ MAPK3 P27361 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL465419 0.89 FGFR1 (0.64) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2347124 0.86 FGFR1 (0.62) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2352805 0.84 FGFR1 (0.61) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL8135009 0.84 FGFR1 (0.83) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2350863 0.83 FGFR1 (0.65) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL1167995 0.83 FGFR1 (0.61) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL1168504 0.83 FGFR1 (0.61) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL12394361 0.82 FGFR1 (0.76) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2351940 0.82 FGFR1 (0.62) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2351943 0.82 FGFR1 (0.62) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008310-B2 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same SANOFI-AVENTIS (FR) 2011-08-30 — — US claimed
US-20090163522-A1 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same SANOFI-AVENTIS (FR) 2009-06-25 — — US claimed
US-20080176874-A1 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same SANOFI-AVENTIS (FR) 2008-07-24 — — US claimed
EP-2020410-B1 Pyrido[2,3-d]pyrimidine derivatives, process for their preparation and their therapeutical use SANOFI SA (FR) 2013-12-18 — — EP disclosed
US-8008310-B2 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same SANOFI-AVENTIS (FR) 2011-08-30 — — US disclosed
US-20090163522-A1 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same SANOFI-AVENTIS (FR) 2009-06-25 — — US disclosed
US-7504406-B2 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same SANOFI-AVENTIS (FR) 2009-03-17 — — US disclosed
EP-2020410-A1 Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use sanofi-aventis (FR) 2009-02-04 — — EP disclosed
US-20080176874-A1 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same SANOFI-AVENTIS (FR) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176874-A1 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same DPYD, TYMP, TYMS FGFR1 2373/4885FGFR2 1763/4885FGFR4 1163/4885
US-20090163522-A1 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same DPYD, TYMP, TYMS FGFR1 2373/4885FGFR2 1763/4885FGFR4 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback